{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:17:29Z","timestamp":1788236249170,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.7759\/cureus.115554","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:47:21Z","timestamp":1788234441000},"source":"Crossref","is-referenced-by-count":0,"title":["A Heterogeneous Phenotypic Presentation of a PALB2 Mutation Carrier With Multiple Metachronous Primary Malignancies: A Case Report"],"prefix":"10.7759","author":[{"given":"Pujita","family":"Julakanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Hugo","family":"Spitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Runko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ziton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18091886","article-title":"The role of PALB2 in the DNA damage response and cancer predisposition","volume":"18","author":"Nepomuceno TC","year":"2017","unstructured":"Nepomuceno TC, De Gregoriis G, de Oliveira FM, Suarez-Kurtz G, Monteiro AN, Carvalho MA. The role of PALB2 in the DNA damage response and cancer predisposition. Int J Mol Sci. 2017, 18:1886. 10.3390\/ijms18091886","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/genes12122002","article-title":"Structural insight into the mechanism of PALB2 interaction with MRG15","volume":"12","author":"Redington J","year":"2021","unstructured":"Redington J, Deveryshetty J, Kanikkannan L, Miller I, Korolev S. Structural insight into the mechanism of PALB2 interaction with MRG15. Genes (Basel). 2021, 12:2002. 10.3390\/genes12122002","journal-title":"Genes (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.6228","article-title":"Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer","volume":"319","author":"Hu C","year":"2018","unstructured":"Hu C, Hart SN, Polley EC, et al.. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018, 319:2401-9. 10.1001\/jama.2018.6228","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families","volume":"38","author":"Yang X","year":"2020","unstructured":"Yang X, Leslie G, Doroszuk A, et al.. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol. 2020, 38:674-85. 10.1200\/JCO.19.01907","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.21037\/tbcr-22-33","article-title":"Risk-reducing surgery in PALB2 mutations carriers with breast cancer: a case series and literature review","volume":"3","author":"Masanam MK","year":"2022","unstructured":"Masanam MK, Pitcher CW, Sogunro O, Starks LK, Murray AB, Boisvert ME. Risk-reducing surgery in PALB2 mutations carriers with breast cancer: a case series and literature review. Transl Breast Cancer Res. 2022, 3:37. 10.21037\/tbcr-22-33","journal-title":"Transl Breast Cancer Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00169","article-title":"Functional characterization of PALB2 variants of uncertain significance: toward cancer risk and therapy response prediction","volume":"7","author":"Boonen RA","year":"2020","unstructured":"Boonen RA, Vreeswijk MP, van Attikum H. Functional characterization of PALB2 variants of uncertain significance: toward cancer risk and therapy response prediction. Front Mol Biosci. 2020, 7:169. 10.3389\/fmolb.2020.00169","journal-title":"Front Mol Biosci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00291-7","article-title":"PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer","volume":"6","author":"Dillon KM","year":"2022","unstructured":"Dillon KM, Bekele RT, Sztupinszki Z, et al.. PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer. NPJ Precis Oncol. 2022, 6:49. 10.1038\/s41698-022-00291-7","journal-title":"NPJ Precis Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70404","article-title":"Breast cancer: molecular pathogenesis and targeted therapy","volume":"6","author":"Samad MA","year":"2025","unstructured":"Samad MA, Ahmad I, Khan MR, et al.. Breast cancer: molecular pathogenesis and targeted therapy. MedComm (2020). 2025, 6:e70404. 10.1002\/mco2.70404","journal-title":"MedComm (2020)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01151-8","article-title":"Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Tischkowitz M","year":"2021","unstructured":"Tischkowitz M, Balma\u00f1a J, Foulkes WD, et al.. Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021, 23:1416-23. 10.1038\/s41436-021-01151-8","journal-title":"Genet Med"},{"key":"ref10","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Genetic\/Familial High-Risk Assessment. Breast, Ovarian, Pancreatic, and Prostate. Accessed: July 10, 2026: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=2&amp;id=1545."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.6204","article-title":"Breast cancer screening strategies for women with ATM, CHEK2, and PALB2 pathogenic variants: a comparative modeling analysis","volume":"8","author":"Lowry KP","year":"2022","unstructured":"Lowry KP, Geuzinge HA, Stout NK, et al.. Breast cancer screening strategies for women with ATM, CHEK2, and PALB2 pathogenic variants: a comparative modeling analysis. JAMA Oncol. 2022, 8:587-96. 10.1001\/jamaoncol.2021.6204","journal-title":"JAMA Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad044","article-title":"Adherence to NCCN genetic testing guidelines in pancreatic cancer and impact on treatment","volume":"28","author":"Crowley F","year":"2023","unstructured":"Crowley F, Gandhi S, Rudshteyn M, Sehmbhi M, Cohen DJ. Adherence to NCCN genetic testing guidelines in pancreatic cancer and impact on treatment. Oncologist. 2023, 28:486-93. 10.1093\/oncolo\/oyad044","journal-title":"Oncologist"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2016-103839","article-title":"PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS","volume":"53","author":"Southey MC","year":"2016","unstructured":"Southey MC, Goldgar DE, Winqvist R, et al.. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016, 53:800-11. 10.1136\/jmedgenet-2016-103839","journal-title":"J Med Genet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1012","article-title":"PALB2\/FANCN: recombining cancer and Fanconi anemia","volume":"70","author":"Tischkowitz M","year":"2010","unstructured":"Tischkowitz M, Xia B. PALB2\/FANCN: recombining cancer and Fanconi anemia. Cancer Res. 2010, 70:7353-9. 10.1158\/0008-5472.CAN-10-1012","journal-title":"Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000172","article-title":"Multiple primary tumours: challenges and approaches, a review","volume":"2","author":"Vogt A","year":"2017","unstructured":"Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, Omlin A. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017, 2:e000172. 10.1136\/esmoopen-2017-000172","journal-title":"ESMO Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/478365-a-heterogeneous-phenotypic-presentation-of-a-palb2-mutation-carrier-with-multiple-metachronous-primary-malignancies-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:47:24Z","timestamp":1788234444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/478365-a-heterogeneous-phenotypic-presentation-of-a-palb2-mutation-carrier-with-multiple-metachronous-primary-malignancies-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.115554","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}